Bibliography
- Bogetto F, Albert U, Maina G. Sertraline treatment of obsessive-compulsive disorder: efficacy and tolerability of a rapid titration regimen. Eur Neuropsychopharmacol 2002;12(3):181-6
- Bernardo M, Buisán E, Durán A, Venlafaxine titration dosage in depressive in-patients. A series of cases. Actas Esp Psiquiatr 2003;31(1):31-4
- Buoli M, Dell'osso B, Bosi MF, Slow vs standard up-titration of paroxetine in the treatment of panic disorder: a prospective randomized trial. Psychiatry Clin Neurosci 2010;64(6):612-19
- Amodeo L, Leombruni P, Torta R, Slow versus standard up-titration of paroxetine for the treatment of depression in cancer patients: a pilot study. Support Care Cancer 2012;20(2):375-84
- Gourion D. Antidepressants and their onset of action: a major clinical methodological and prognostical issue. Encephale 2008;34(1):73-81
- Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther 2003;25(8):2289-304
- Aikens JE, Nease DE Jr, Nau DP, Adherence to maintenance-phase antidepressant medication as a function of patient beliefs about medication. Ann Fam Med 2005;3:23-30
- World Health Organization. Adherence to long-term therapies: evidence for action. WHO; Geneva: 2003
- Adler RH. Engel's biopsychosocial model is still relevant today. J Psychosom Res 2009;67(6):607-11
- Chopra K, Kumar B, Kuhad A. Pathobiological targets of depression. Expert Opin Ther Targets 2011;15(4):379-400
- Stein MB, Goin MK, Pollack MH, Practice guideline for the treatment of patients with panic disorder. 2nd edition. American Psychiatric Press; Washington, DC: 2009
- Katz AJ, Dusetzina SB, Farley JF, Distressing Adverse events after antidepressant switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial: influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an alternative antidepressant. Pharmacotherapy 2012; [Epub ahead of print]
- Reiner I, Spangler G. Dopamine D4 receptor exon III polymorphism, adverse life events and personality traits in a nonclinical German adult sample. Neuropsychobiology 2011;63(1):52-8
- Buskila D. Developments in the scientific and clinical understanding of fibromyalgia. Arthritis Res Ther 2009;11(5):242
- Wilhelm S, Boess FG, Hegerl U, Tolerability aspects in duloxetine-treated patients with depression: should one use a lower starting dose in clinical practice? Expert Opin Drug Safety 2012;11(5):699-711
- Yevtushenko OO, Oros MM, Reynolds GP. Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism. J Affect Disord 2010;123(1-3):308-11
- Watanabe T, Ueda M, Saeki Y, High plasma concentrations of paroxetine impede clinical response in patients with panic disorder. Ther Drug Monit 2007;29(1):40-4
- Berra C, Torta R. Therapeutic rationale of antidepressant use in the elderly. Arch Gerontol Geriatr 2007;44(1):83-90
- Rodriguez de la Torre B, Dreher J, Malevany I, Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther Drug Monit 2001;23(4):435-40
- Whitmyer VG, Dunner DL, Kornstein SG, A comparison of initial duloxetine dosing strategies in patients with major depressive disorder. J Clin Psychiatry 2007;68(12):1921-30
- Wheeler A, Robinson G, Fraser A. Mood stabilizer loading versus titration in acute mania: audit of clinical practice. Aust NZ J Psychiatry 2008;42(11):955-62
- Hurley SC. Lamotrigine update and its use in mood disorders. Ann Pharmacother 2002;36(5):860-73
- Haanpää ML, Gourlay GK, Kent JL, Treatment considerations for patients with neuropathic pain and other medical comorbidities. Mayo Clin Proc 2010;85(3 Suppl):S15-25